Welcome to MediciNova
MediciNova in the News
MediciNova’s Drug Trial Addresses Methamphetamine Dependency - San Diego Business Journal - September 24, 2012
Michael Coffee, Chief Business Officer, talks on eHealth Radio Network about a new asthma treatment to a new addiction treatment - September 7, 2012
Dr. Yuichi Iwaki selected as one of the 100 of the Most Inspiring People in PharmaVoice July/August 2012 - Introduction - Full Article
Click to watch a segment featuring MN-221 by NBC Philadelphia.
Click here for more stories at MediciNova's Media Archive
MediciNova Featured on NBC's Better Life Guide - Biotech N' You
Click for more information on our Core Candidates:
MN-221 Update:
January 3, 2013 - MediciNova, Inc. provides a development update on its two lead programs, MN-221 and MN-166.
End-of-phase 2 guidance from the FDA and the newly extended patent protection (to expire no earlier than 2030) for use of MN-221 in the treatment of acute exacerbations of asthma (AEA) provide a clear development path for MN-221.
MN-166 Update:
January 3, 2013 - MediciNova, Inc. provides a development update on its two lead programs, MN-221 and MN-166.
MediciNova will leverage its MN-166 neurological program with grant-aided Phase 2 studies to advance MN-166 towards regulatory approval, initially in drug dependence. A phase 2 trial in methamphetamine dependence is scheduled to start in first half 2013 and could lead to MN-166 becoming the first FDA-approved product for treatment of methamphetamine dependence.
MediciNova's Corporate Presentation
About MediciNova
MediciNova, Inc. is a publicly traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a commercial focus on the U.S. market.
Order Preliminarily Approving Settlement and Providing for Notice
